The FreeStyle Libre 3 is the smallest continuous glucose monitor available — about the size of two stacked pennies — and the first Abbott CGM that streams readings every minute via continuous Bluetooth without requiring a scan. It is FDA-cleared for adults and children 4 and older, lasts 14 days per sensor, and reports a mean absolute relative difference (MARD) of approximately 7.9 percent.
What Makes the Libre 3 Different
The Libre 3 is the third generation of Abbott’s flash glucose monitoring line. Earlier Libre 1 and Libre 2 sensors required scanning with a phone or reader to retrieve glucose data, with the Libre 2 adding optional Bluetooth alerts. The Libre 3 removed the scan step entirely. The sensor pairs once with your phone and streams a fresh glucose value every 1 minute over Bluetooth Low Energy. This produces more granular data than the 5-minute interval used by older models and most competitors. The sensor body is dramatically smaller — Abbott describes it as the size of two stacked US pennies — making it less visible under clothing.
How the Sensor Works
Like all current CGMs, the FreeStyle Libre 3 measures glucose in interstitial fluid (the fluid between cells just under the skin) rather than directly in blood. A small filament about 5 mm long sits beneath the skin after insertion. A glucose oxidase reaction at the filament tip generates a small electrical signal proportional to the glucose concentration. The sensor electronics translate that signal into a glucose value and transmit it to the paired phone app every minute. Insertion uses a single-piece applicator that places the sensor in one motion, and most users describe minimal discomfort. The sensor is water-resistant for showering, swimming, and exercise within manufacturer-specified depths and durations.
| Specification | FreeStyle Libre 3 |
|---|---|
| Wear duration | 14 days |
| Reading interval | 1 minute |
| Warm-up time | 60 minutes |
| Calibration | None required (factory-calibrated) |
| Reported MARD | Approximately 7.9 percent |
| Approved age | 4 years and older |
| Connectivity | Continuous Bluetooth Low Energy |
| App | FreeStyle Libre 3 (iOS and Android) |
| Sensor size | Approximately 21 mm diameter, 2.9 mm thick |
The FreeStyle Libre 3 App
The FreeStyle Libre 3 app for iOS and Android replaces the standalone reader for most users. It displays the current glucose value, a trend arrow, and a continuous graph of the last several hours. Customizable high and low alerts can be enabled, and the app generates daily, weekly, and biweekly reports including time in range, average glucose, and the Glucose Management Indicator (GMI). LibreView and LibreLinkUp let healthcare providers and family members view your data remotely with your permission. The app also supports logging meals, activity, and insulin doses for context alongside glucose trends.
Accuracy and FDA Clearance
The FreeStyle Libre 3 received FDA clearance in May 2022 for adults and children 4 and older with diabetes. According to Abbott’s submission and the corresponding FDA review, the overall MARD compared with reference YSI plasma glucose was approximately 7.9 percent in adults and within similar ranges in pediatric populations. MARD is the average percentage difference between CGM and laboratory glucose values; current top-tier CGMs (Libre 3, Dexcom G7) report MARD values in the 7 to 9 percent range. Accuracy can be slightly lower during very rapid glucose changes and at very low or very high values.
How Libre 3 Compares to Other CGMs
The two main competitors are the Dexcom G7 and the over-the-counter Stelo (Dexcom) and Lingo (Abbott) sensors aimed at non-diabetes wellness use. The Eversense E3 and 365 are implantable CGMs that sit under the skin for 6 to 12 months but require an in-office insertion procedure.
| CGM | Wear | Reading Interval | Reported MARD | OTC? |
|---|---|---|---|---|
| FreeStyle Libre 3 | 14 days | 1 minute | ~7.9 percent | No (Rx) |
| Dexcom G7 | 10 days | 5 minutes | ~8.2 percent | No (Rx) |
| Stelo (Dexcom) | 15 days | 15 minutes | Not for treatment decisions | Yes |
| Lingo (Abbott) | 14 days | 1 minute | Wellness use only | Yes |
| Eversense 365 | 365 days (implant) | 5 minutes | ~8.5 percent | No (Rx) |
Insurance, Cost, and Coverage
FreeStyle Libre 3 sensors are covered by Medicare Part B for people on insulin therapy who meet criteria for therapeutic CGM use. Most commercial insurance plans cover Libre 3 for insulin-treated diabetes, and increasingly for non-insulin type 2 diabetes when prescribed for management of recurrent hypoglycemia or unstable glucose. Without insurance, the sensors typically cost roughly 70 to 90 dollars each (about 145 to 185 dollars per month). Abbott offers a savings program through MyFreeStyle for eligible commercially insured patients. For broader context on glucose testing options, see our detection of prediabetes guide and the A1C levels hub.
Insertion Sites and Practical Tips
The FDA-approved insertion site for the Libre 3 is the back of the upper arm. Rotate sites between the left and right arm with each new sensor to avoid skin irritation. Use the included alcohol wipe to clean the site, allow it to dry completely, and apply firm pressure when inserting. Adhesive overpatches are widely available for athletes, swimmers, or anyone who has experienced sensor lift. A 60-minute warm-up follows insertion before the first reading appears. To support your data with everyday choices, our diet and nutrition hub covers food patterns that influence postprandial glucose.
The Bottom Line
The FreeStyle Libre 3 is Abbott’s smallest, most accurate, and most user-friendly CGM, with 14-day wear, 1-minute streaming readings, factory calibration, and FDA clearance for ages 4 and older. Reported MARD around 7.9 percent puts it on par with the Dexcom G7. It is appropriate for most people with diabetes, particularly those on insulin, and is increasingly available with insurance coverage. Talk with your prescriber about whether the Libre 3 or another CGM best matches your treatment plan.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
